Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03780634 | HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03803254 | HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03782831 |
| TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC |
| withdrawn |
| Phase 2 |
| 0 |
| Sun Yat-sen UniversityOTHER |
| 1 |
| May 2, 2019 |
| clinicaltrials |
| NCT02471313 | Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization | completed | Phase 2 | 3 | National Institutes of Health Clinical Center (CC)NIH | 1 | Apr 23, 2019 | clinicaltrials |
| NCT03746249 | Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03812770 | Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC | unknown | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT02950025 | Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies | terminated | Phase 2 | 5 | Washington University School of MedicineOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT00735917 | Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 3 | Apr 2, 2019 | clinicaltrials |
| NCT03857815 | Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01760252 | Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol | terminated | Phase 2 | 17 | Beth Israel Medical CenterOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT01233375 | Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma | completed | Phase 2 | 19 | Clovis Oncology, Inc.INDUSTRY | 1 | Mar 11, 2019 | clinicaltrials |
| NCT02981498 | Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma | completed | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT01290536 | Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases | completed | Phase 2 | 42 | Nicholas Fidelman, MDOTHER | 0 | Mar 1, 2019 | clinicaltrials |
| NCT02267213 | Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma | terminated | Phase 2 | 29 | Taiwan Liposome CompanyINDUSTRY | 2 | Feb 26, 2019 | clinicaltrials |
| NCT02425605 | Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 47 | Yonsei UniversityOTHER | 1 | Feb 25, 2019 | clinicaltrials |
| NCT03851887 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03851939 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 65 | Sun Yat-sen UniversityOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT02440958 | Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial | completed | Phase 2 | 50 | Yonsei UniversityOTHER | 0 | Feb 18, 2019 | clinicaltrials |
| NCT01484860 | Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy | terminated | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03839550 | Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection | unknown | Phase 2 | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02005419 | Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection | completed | Phase 2 | 300 | Xian-Jun YuOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT02023021 | Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection | completed | Phase 2 | 80 | Xian-Jun YuOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT00946153 | Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 66 | Eisai Co., Ltd.INDUSTRY | 2 | Feb 1, 2019 | clinicaltrials |
| NCT02053376 | A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy | completed | Phase 2 | 43 | Nathan Bahary, MDOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 25 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 30, 2019 | clinicaltrials |
| NCT03779100 | Lenvatinib Plus PD-1 Antibody for Unresectable ICC | suspended | Phase 2 | 25 | Shi MingOTHER | 1 | Jan 28, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT01306058 | Sorafenib and TRC105 in Hepatocellular Cancer | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03812783 | HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02191878 | Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 43 | Arbutus Biopharma CorporationINDUSTRY | 6 | Jan 16, 2019 | clinicaltrials |
| NCT02220088 | The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial | terminated | Phase 2 / Phase 3 | 79 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT01210495 | Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma | completed | Phase 2 | 224 | PfizerINDUSTRY | 13 | Jan 9, 2019 | clinicaltrials |
| NCT03793725 | A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC(HZ-T-PD1-APA) | unknown | Phase 2 | 30 | Yanqiao ZhangOTHER | 0 | Jan 4, 2019 | clinicaltrials |
| NCT03116945 | Novel Gallium Imaging in Hepatocellular Carcinoma | unknown | Phase 2 | 18 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02759601 | Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)(CHR-2845) | unknown | Phase 1 / Phase 2 | 69 | Queen Mary University of LondonOTHER | 1 | Dec 20, 2018 | clinicaltrials |
| NCT01258608 | Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 101 | Human Genome Sciences Inc., a GSK CompanyINDUSTRY | 7 | Dec 19, 2018 | clinicaltrials |
| NCT03732547 | Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT01855724 | Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer | terminated | Phase 2 | 29 | Hellenic Cooperative Oncology GroupOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT03035006 | Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis | terminated | Phase 1 / Phase 2 | 1 | Taiwan Liposome CompanyINDUSTRY | 1 | Nov 6, 2018 | clinicaltrials |
| NCT03702491 | Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma | unknown | Phase 2 | 138 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Oct 11, 2018 | clinicaltrials |
| NCT02181634 | Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma(PrE0204) | completed | Phase 2 | 74 | PrECOG, LLC.OTHER | 2 | Oct 3, 2018 | clinicaltrials |
| NCT02254681 | Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC | terminated | Phase 2 | 6 | Allina Health SystemOTHER | 1 | Oct 3, 2018 | clinicaltrials |
| NCT01395030 | PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection | completed | Phase 2 | 64 | Queen's Medical CenterOTHER | 1 | Sep 26, 2018 | clinicaltrials |
| NCT02006030 | Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma(TACE) | completed | Phase 2 | 30 | Polaris GroupINDUSTRY | 1 | Sep 4, 2018 | clinicaltrials |
| NCT03633773 | Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma | unknown | Phase 1 / Phase 2 | 9 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT01425996 | A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 3 | Taiwan Liposome CompanyINDUSTRY | 1 | Aug 21, 2018 | clinicaltrials |
| NCT02558894 | Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 2 | 65 | AstraZenecaINDUSTRY | 6 | Aug 2, 2018 | clinicaltrials |
| NCT01921751 | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 20 | Radiation Therapy Oncology GroupNETWORK | 1 | Jul 13, 2018 | clinicaltrials |
| NCT02345460 | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | terminated | Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT00832637 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox) | terminated | Phase 2 | 33 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 29, 2018 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2019source: clinicaltrials